Blockade of Extracellular High-Mobility Group Box 1 Attenuates Systemic Inflammation and Coagulation Abnormalities in Rats with Acute Traumatic Coagulopathy.

Background: As an extracellularly released mediator, high-mobility group box 1 (HMGB1) initiates sterile inflammation following severe trauma. Serum HMGB1 levels correlate well with acute traumatic coagulopathy (ATC) in trauma patients, which is independently associated with higher mortality. We investigated the involvement of HMGB1 in ATC through blocking extracellular HMGB1. Material/Methods: The ATC model was induced by polytrauma and hemorrhage in male Sprague-Dawley rats, which were randomly assigned to sham, ATC, and ATCH (ATC with HMGB1 blockade) groups. Thrombelastography (TEG) was performed to monitor changes in coagulation function. Serum levels of HMGB1, TNF-alpha, and IL-6 were measured, as well as lung levels of HMGB1 and nuclear factor (NF)-kappa B and expression of receptor for advanced glycation end-products (RAGE). Results: Compared with the sham group, HMGB1 increased the serum levels of TNF-alpha and IL-6, whereas HMGB1 blockade inhibited the induction of TNF-alpha and IL-6. HMGB1 also induced elevated serum soluble P-selectin and fibrinolysis markers plasmin-antiplasmin complex, which both were reduced by HMGB1 blockade. Thrombelastography revealed the hypocoagulability status in the ATC group, which was attenuated by anti-HMGB1 antibody. Furthermore, the lung level of NF-kappa B and expression of RAGE were decreased by anti-HMGB1 antibody, suggesting the role of RAGE/NF-kappa B pathway in ATC. Conclusions: HMGB1 blockade can attenuate inflammation and coagulopathy in ATC rats. Anti-HMGB1 antibody might exert protective effects partly through the RAGE/NF-kappa B pathway. Thus, HMGB1 has potential as a therapeutic target in ATC.